DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing ...
Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...
The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...
Dr. Dina Radenkovic, CEO of Gameto, identifies the main contributors to the gap in in women's health innovation.
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics ...
In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...
Dr. Dina Radenkovic, CEO of Gameto, identifies strategies to close the gap in women's health and how we can better incentivize research and development in this area.
In an era where business-critical information is exchanged instantly, unsecured communication channels are a significant risk.
A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback